terbogrel + clopidogrel

Terbogrel + clopidogrel is an **investigational oral combination therapy** for the prevention of thromboembolic events, notably in acute coronary syndromes and related vascular conditions. It combines **terbogrel**, a potent dual inhibitor of **thromboxane A2 (TxA2) synthase** and a **TxA2 receptor antagonist** (blocking both the production and action of TxA2, which promotes platelet aggregation and vasoconstriction), and **clopidogrel**, a **P2Y12 receptor antagonist** that inhibits ADP-induced platelet aggregation. The rationale behind the combination is to offer **complementary antiplatelet effects**: terbogrel targets the thromboxane pathway to block prothrombotic and vasoconstrictive signals and enhance prostacyclin production, while clopidogrel suppresses a separate platelet activation pathway, providing broader inhibition of platelet aggregation. Both agents are administered orally and have been studied as antithrombotic therapies, especially in patients intolerant to or inadequately controlled by aspirin[1][2].